The conversation discusses the use of castor oil and pumpkin seed oil for hair thickness and shine, with concerns about oral consumption. The user is already using Minoxidil, finasteride, and RU58841.
PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.
Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
Finasteride is essential for hair loss prevention, while minoxidil is optional. Additional treatments include a natural shampoo, a healthy diet, scalp massages, microneedling, laser therapy, and supplements like fish oils and biotin.
A hair loss treatment protocol involving topical and oral medications such as Minoxidil, RU58841, Finasteride, Dutasteride, Melatonin, Zinc, Vitamin B6, NAC, Caffeine, Biotin, Ginseng, and Semen; other treatments including Microneedling, Laser Helmet, Nizoral shampoo, Scalp Massage and supplements like Vitamin C, Vitamin D, Fish Oil, and Biotin; and the potential side effects of using this protocol.
The conversation discusses hair regrowth treatments, including stem cell exosomes, PRP, and PP405. Users question the effectiveness of the treatments and mention finasteride and minoxidil.
User discusses using finasteride, ketoconazole, fish oil, nettle root, saw palmetto, emu oil, and plans to start minoxidil for hair loss. They report maintaining hair with minor side effects like slightly lower libido and watery semen.
Finasteride and dutasteride are essential for stopping hair loss, while natural remedies are ineffective. Minoxidil can be added if needed, but blocking DHT is crucial.
PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.